Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,606 public trials 492 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Active, Not Recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • City of Hope Duarte, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • Yale University New Haven, Connecticut, United States
View all 176 locations
View Trial Details
Active, Not Recruiting

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

NCT05556798

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT03798678

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Yale University New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
View Trial Details
Active, Not Recruiting

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

NCT03896737

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease, +15 more
Locations
  • Hradec Kralove-University Hospital Hradec Kralove Hradec Králové, Czechia
  • University Hospital Olomouc Olomouc, Czechia
  • University Hospital Ostrava Ostrava, Czechia
  • University Hospital Ostrava Ostrava, Czechia
View all 24 locations
View Trial Details

Related conditions